Hopantenic acid
Inside, 15-30 minutes after eating.
A single dose for adults is usually 250-1000 mg, for children - 250-500 mg; daily dose for adults - 1500 mg to 3000 mg, for children - from 750 mg to 3000 mg. The course of treatment is from 1 to 4 months, in some cases up to 6 months. After 3-6 months, a second course of treatment is possible.
For cognitive impairment with organic brain lesions, including the consequences of neuroinfections and traumatic brain injuries, and neurotic disorders: 250 mg 3-4 times a day.
For extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with ongoing therapy: in a dose of 500 mg to 3000 mg per day. The course of treatment is up to 4 months or more.
As a corrector for the side effects of neuroleptic drugs, for neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral organic failure in patients with schizophrenia: adults - in a dose of 500 mg to 1000 mg 3 times a day; children - in a dose of 250 mg to 500 mg 3-4 times a day. The course of treatment is 1-3 months.
For epilepsy with slowing of mental processes in complex therapy with anticonvulsants: adults - in a dose of 500 mg to 1000 mg 3 times a day; children - in a dose of 250 mg to 500 mg 3-4 times a day. The course of treatment is up to 6 months.
For psycho-emotional overload, decreased mental and physical performance, to improve concentration and memory: 250 mg 3 times a day.
For neurogenic urination disorders: adults - in a dose of 500 mg to 1000 mg 2-3 times a day; children - in a dose of 250 mg to 500 mg 3 times a day (daily dose is 25-50 mg/kg). The course of treatment is 1-3 months.
For children with various pathologies of the nervous system, depending on age, it is recommended to take the drug up to 3000 mg per day. Tactics for prescribing the drug: increasing the dose over 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose until discontinuation of Hopantenic acid over 7-8 days. The break between course doses of Hopanthenic acid, as for any other nootropic drug, ranges from 1 to 3 months.
Children with developmental delay: 500 mg 3-4 times a day. The course of treatment is 2-3 months.
Children with attention deficit hyperactivity disorder: depending on body weight, the drug is prescribed at an average therapeutic dose of 30 mg/kg per day, morning and afternoon, with dose titration over the first 5-7 days. The course of treatment is 3-4 months.
For children with neurosis-like conditions (tics; stuttering, mainly in the tonic form): in a dose of 250 mg to 500 mg 3-6 times a day. The course of treatment is 1-4 months.
Taking into account the nootropic effect of the drug, it is preferably taken in the morning and afternoon (up to 17:00).
The drug is used in children over 3 years of age. At an earlier age, it is recommended to take the drug in syrup form.
Hopanthenic acid 500 mg 50 pcs. pills
pharmachologic effect
Nootropic drug.
Composition and release form Hopanthenic acid 500 mg 50 pcs. pills
Tablets - 1 tablet:
- active ingredient: calcium hopantenate - 500 mg;
- excipients: hydroxypropyl methylcellulose (hypromellose) - 15.0 mg, magnesium hydroxycarbonate pentahydrate (magnesium carbonate basic aqueous) - 80.2 mg, talc - 18.6 mg; calcium stearate - 6.2 mg.
10 tablets per contour cell packaging made of PVC film and aluminum foil.
20 tablets in BP type polymer jars made of low-density polyethylene with high-density polyethylene caps or in polymer bottles made of low-density polyethylene with high-density polyethylene caps.
Each jar or bottle, 4, 5, 6 blister contour packages along with instructions for use are placed in a cardboard pack.
Description of the dosage form
Tablets are white or almost white, round, flat-cylindrical with a chamfer and a score on one side.
Directions for use and doses
Inside, 15-30 minutes after eating.
A single dose for adults is usually 250-1000 mg, for children - 250-500 mg; daily dose for adults - 1500 mg to 3000 mg, for children - from 750 mg to 3000 mg. The course of treatment is from 1 to 4 months, in some cases up to 6 months. After 3-6 months, a second course of treatment is possible.
For cognitive impairment with organic brain lesions, including the consequences of neuroinfections and traumatic brain injuries, and neurotic disorders: 250 mg 3-4 times a day.
For extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with ongoing therapy: in a dose of 500 mg to 3000 mg per day. The course of treatment is up to 4 months or more.
As a corrector for the side effects of neuroleptic drugs, for neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral organic failure in patients with schizophrenia: adults - in a dose of 500 mg to 1000 mg 3 times a day; children - in a dose of 250 mg to 500 mg 3-4 times a day. The course of treatment is 1-3 months.
For epilepsy with slowing of mental processes in complex therapy with anticonvulsants: adults - in a dose of 500 mg to 1000 mg 3 times a day; children - in a dose of 250 mg to 500 mg 3-4 times a day. The course of treatment is up to 6 months.
For psycho-emotional overload, decreased mental and physical performance, to improve concentration and memory: 250 mg 3 times a day.
For neurogenic urination disorders: adults - in a dose of 500 mg to 1000 mg 2-3 times a day; children - in a dose of 250 mg to 500 mg 3 times a day (daily dose is 25-50 mg/kg). The course of treatment is 1-3 months.
For children with various pathologies of the nervous system, depending on age, it is recommended to take the drug up to 3000 mg per day. Tactics for prescribing the drug: increasing the dose over 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose until discontinuation of Hopantenic acid over 7-8 days. The break between course doses of Hopanthenic acid, as for any other nootropic drug, ranges from 1 to 3 months.
Children with developmental delay: 500 mg 3-4 times a day. The course of treatment is 2-3 months.
Children with attention deficit hyperactivity disorder: depending on body weight, the drug is prescribed at an average therapeutic dose of 30 mg/kg per day, morning and afternoon, with dose titration over the first 5-7 days. The course of treatment is 3-4 months.
For children with neurosis-like conditions (tics; stuttering, mainly in the tonic form): in a dose of 250 mg to 500 mg 3-6 times a day. The course of treatment is 1-4 months.
Taking into account the nootropic effect of the drug, it is preferably taken in the morning and afternoon (up to 17:00).
The drug is used in children over 3 years of age. At an earlier age, it is recommended to take the drug in syrup form.
Pharmacodynamics
The spectrum of action of hopantenic acid is associated with the presence of gamma-aminobutyric acid in its structure. The mechanism of action is due to the direct effect of the drug on the GABAB receptor-channel complex. The drug has a nootropic and anticonvulsant effect. Increases the brain's resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, and activates mental and physical performance. Improves GABA metabolism during chronic alcohol intoxication and after ethanol withdrawal. It is capable of inhibiting acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of the pathologically increased bladder reflex and detrusor tone.
Pharmacokinetics
Hopanthenic acid is quickly absorbed from the gastrointestinal tract, penetrates the blood-brain barrier, the highest concentrations are created in the liver, kidneys, stomach wall and skin. The drug is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken is in the urine, 28.5% is in the feces.
Indications for use Hopanthenic acid 500 mg 50 pcs. pills
- Cognitive impairment in organic brain lesions, including the consequences of neuroinfections and traumatic brain injuries and neurotic disorders;
- for extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with ongoing therapy;
- as a corrector for the side effects of neuroleptic drugs, for neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral organic failure in patients with schizophrenia;
- epilepsy with slowing of mental processes in complex therapy with anticonvulsants;
- psycho-emotional overload, decreased mental and physical performance, to improve concentration and memory;
- neurogenic urinary disorders (pollakiuria, urgency, imperative urinary incontinence, enuresis);
- children with developmental delays (mental, speech, motor, or a combination thereof), including those caused by perinatal encephalopathy and children with various forms of cerebral palsy;
- children with hyperkinetic disorders (attention deficit hyperactivity disorder);
- children with neurosis-like conditions (tics; stuttering, mainly in the clonic form).
Contraindications
- Hypersensitivity;
- acute severe kidney disease;
- pregnancy;
- breastfeeding period;
- children under 3 years of age.
With caution: in conditions of long-term treatment, simultaneous administration of the drug with other nootropic and stimulant drugs is not recommended.
Application Hopanthenic acid 500 mg 50 pcs. pills during pregnancy and breastfeeding
The use of the drug during pregnancy and breastfeeding is not recommended due to the lack of experience in clinical use in this category of patients.
special instructions
The drug is used in children over 3 years of age.
In conditions of long-term treatment, simultaneous administration of the drug with other nootropic and stimulant drugs is not recommended.
Impact on the ability to drive vehicles and operate machinery
In the first days of taking the drug, caution should be exercised when driving vehicles and machinery, taking into account the possible occurrence of drowsiness.
Overdose
Symptoms: sleep disturbances or drowsiness, noise in the head.
Treatment: activated carbon, gastric lavage, symptomatic therapy.
Side effects Hopanthenic acid 500 mg 50 pcs. pills
Adverse reactions presented below are listed according to damage to organs and systems and frequency of occurrence. The frequency of occurrence is defined as follows: very often (≥ 1/10), often (≥ 1/100 and
Immune system disorders.
Very rare: allergic reactions (rhinitis, conjunctivitis, allergic skin reactions).
Nervous system disorders.
Very rare: hyperexcitation, headache, dizziness, noise in the head.
Mental disorders.
Very rare: lethargy, lethargy, sleep disturbances, drowsiness.
If disorders of the immune system occur, discontinue the drug. In other cases, reduce the dose of the drug.
Drug interactions
Prolongs the effect of barbiturates, enhances the effect of anticonvulsants, prevents the side effects of phenobarbital, carbamazepine, and neuroleptics. The effect of the drug Hopanthenic acid is enhanced in combination with glycine and etidronic acid. Potentiates the effect of local anesthetics (procaine).
